



Akerro Therapeutics to Present at the Jefferies Global Healthcare Conference

May 29, 2024

SOUTH SAN FRANCISCO, Calif., May 29, 2024 (GLOBE NEWSWIRE) -- Akerro Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, today announced that management will present at the Jefferies Global Healthcare Conference on Wednesday, June 5, 2024, at 4:00 p.m. E.T. in New York, NY.

A live webcast of the Company presentation will be available through the investor relations section of the Company's website at www.akerotx.com. Following the live webcast, an archived replay will be available on the Company's website.

About Akerro Therapeutics

Akerro Therapeutics is a clinical-stage company developing transformational treatments for patients with serious metabolic diseases marked by high unmet medical need, including MASH. Akerro's lead product candidate, EFX, is currently being evaluated in the ongoing SYMMETRY study, a 96-week Phase 2b clinical trial in patients with compensated cirrhosis due to MASH (F4 fibrosis), as well as two ongoing Phase 3 clinical trials: the SYNCHRONY *Histology* study in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and the SYNCHRONY *Real-World* study in patients with MASH (F1-F3 fibrosis) or MASLD. A third clinical trial, the SYNCHRONY *Outcomes* study in patients with compensated cirrhosis due to MASH (F4 fibrosis), is expected to be initiated in the second quarter of 2024. The Phase 3 SYNCHRONY program builds on the results of two Phase 2b clinical trials, the HARMONY study in patients with pre-cirrhotic MASH (F2-F3) and the SYMMETRY study in patients with compensated cirrhosis due to MASH (F4). Akerro is headquartered in South San Francisco. Visit us at akerotx.com and follow us on [LinkedIn](#) and [X](#) for more information.

Investor Contact:

Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com

Media Contact:

Sarah O'Connell
732.456.0092
soconnell@vergescientific.com